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Diabetes Mellitus is a chronic metabolic disorder 
characterized by persistent hyperglycemia and disorders 
of carbohydrate, protein and lipid metabolism.1 It is 
expected that by the year 2030, about 552 million people 
globally will be affected from diabetes mellitus.2 If not well 
controlled, diabetes mellitus leads to both microvascular 
and macrovascular complications.2 Diabetic mellitus is the 
most common cause of diabetes nephropathy that has a 
momentous impact on quality of life and survival of the 
patient.1 It is estimated that about 40 % of type I and type 
II diabetes mellitus develop diabetic kidney disease.2 If 
not timely diagnosed and properly treated, diabetic 
nephropathy eventually leads to End stage renal disease 
that requires dialysis or renal transplantation. Multiple 
serum and urinary biomarkers are used to diagnose 
diabetic nephropathy before it is clinically evident.2 
Urinary microalbumin has been used as a clinical 
biomarker of diabetic kidney disease since 1982.4 It is 
used to screen both type I and type II diabetes mellitus.5 
Microalbuminuria results when albumin crosses 
glomerular filtration barrier due to ultrastructural changes 
in endothelial glycocalyx.6 Microalbuminuria also 
represents a marker of systemic endothelial dysfunction 
with increased risk of cardiovascular and cerebral insults 
in patients with diabetes mellitus.7 
In addition to glomerular injury, newer biomarkers of 
tubular, vascular, inflammation, podocytes and oxidative 
stress have been verified in some patients that detect 
diabetic nephropathy much earlier than 
microalbuminuria.3 Usefulness of these biomarkers is still 
debatable in research due to limited studies performed 
and requires further validation.3 Microalbuminuria even 
disputed as biomarker of early diabetic nephropathy, is 
still considered as an important screening test to detect 
glomerular and tubular injury in diabetic population.3 
American Diabetes Association guidelines recommend 
initial assessment of urinary albumin excretion in type I 
diabetes mellitus who have had diabetes for at least five 
years and in all patients with type II diabetes mellitus at 
the time of presentation and during pregnancy.8 All 
diabetic patients with negative screening test for 
microalbuminuria should be assessed for kidney functions 
on annual basis.9 
Microalbuminuria (although a misnomer term) is detection 
of small quantity of albumin (and not small-size albumin) 
in the urine i.e. 30-300 mg/24 hours or 20 to 200 µg/min 
in the absence of clinical proteinurea as measured by 
standard analytical methods.7 More appropriate term for 
microalbuminuria is paucialbuminuria or albumin excretion 
rate.10 
Normal urinary albumin excretion is less than 30 mg/24 
hours (20ug/min). This small amount is not detectable by 
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routine dipstick method of urine analysis.11 Spot urinary 
albumin to creatinine ratio is more useful indicator and is 
comparable to 24 hours urine collections. Measurement of 
albumin to creatinine ratio (ACR) eliminates variations in 
urine flow rate on a spot urine specimen.11 
Albumin to creatinine ratio of 30 to 300 mg/g of creatinine 
suggests that albumin excretion is between 30 and 
300 mg/24 hours and, therefore, microalbuminuria is 
present. ACR value of >300 mg/g or >300 mg/24 hours 
are indicative of macroalbuminuria or clinical proteinurea. 
This classification system requires that at least two of 
three specimens fall within the microalbuminuric or 
macroalbuminuric range over a 3 to 6 months period. 
Factors that influence urinary albumin excretion must be 
taken into consideration. These factors include high grade 
fever, sever infection exercise within 24 hours, congestive 
cardiac failure, severe hyperglycemia and high blood 
pressure.9  
It is recommended that urinary protein may first be tested 
by routine dipstick method on spot urine sample to rule 
out overt proteinuria. This practice avoids loss of 
laboratory resources and manages work load. When 
urinary protein by dipstick is negative, only then spot urine 
sample should be tested for microalbuminuria or albumin 
to creatinine ratio. 
Microalbuminuria has a variable progression. It can revert 
to normal, progress to macroalbuminuria or can remain 
static.   Interventions like good glycemic control, use of 
angiotensin converting enzyme inhibitors and angiotensin 
II receptor blockers for control of blood pressure reduce 
microalbuminuria and prevent further loss of renal 
functions.3 
Concomitant analysis of several urinary biomarkers along 
with microalbuminuria can diagnose early diabetic 
nephropathy. However, discovery of a new and ideal 
urinary biomarker that is more sensitive and specific than 
microalbuminuria is still awaited. Early detection of 
diabetic kidney disease with such newer biomarkers in 
future will minimize renal complications of diabetes 
mellitus by appropriate and timely interventions.3 
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